# A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients

> **NCT03485326** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1700 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03485326
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-21
- **Primary completion:** 2023-08-03
- **Final completion:** 2023-08-03
- **Target enrollment:** 1700 (ACTUAL)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03485326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03485326, "A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03485326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*